CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: March 30, 2015
Result type: Reports
Project Number: SR0429-000
Product Line: Reimbursement Review

Generic Name: Ivermectin

Brand Name: Rosiver

Manufacturer: Galderma Canada Inc.

Therapeutic Area: Rosacea

Indications: Rosacea

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: November 19, 2015

Recommendation Type: List with criteria/condition